Sofinnova BioEquities, LP
Sofinnova BioEquities, LP is a hedge fund based in Menlo Park, California. According to its most recent Form D, filed May 8, 2026, the fund has sold $376,921,569 of interests to 77 investors since its first sale in Jan 2017. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Sofinnova Investments, Inc; Sofinnova BioEquities GP LLC.
Performance
No verified returns have been reported for this fund. As a rough guide, Sofinnova Investments, Inc., which manages it, disclosed U.S. stock holdings that returned an estimated +20.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based only on its public 13F filings. Over a longer period, Q3 2024 to Q2 2026, the estimate is +84.2% (S&P 500: +37.2%).
This estimate covers the firm's whole disclosed long U.S. stock portfolio. It is not this fund's return and excludes dividends, fees, shorts, derivatives, bonds, cash and trading within each quarter.
Is this your fund? Report your monthly returns · How performance works
- Total raised
- $376,921,569Cumulative sales reported on Form D
- Investors
- 77
- First sale
- Jan 3, 2017
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Sofinnova Investments, Inc; Sofinnova BioEquities GP LLC
- Latest Form D
- May 8, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Sofinnova BioEquities, LP
What is the minimum investment for Sofinnova BioEquities, LP?
Sofinnova BioEquities, LP's latest Form D, filed May 8, 2026, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Sofinnova BioEquities, LP?
Sofinnova BioEquities, LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Sofinnova BioEquities, LP raised?
Sofinnova BioEquities, LP reports $376,921,569 sold from 77 investors on its Form D filed May 8, 2026. This is cumulative sales since the offering began, not current assets or performance.
Where is Sofinnova BioEquities, LP based?
Sofinnova BioEquities, LP is based in Menlo Park, California and is managed by Sofinnova Investments, Inc..
When did Sofinnova BioEquities, LP launch?
Sofinnova BioEquities, LP reports its first sale in Jan 2017.
Size compared with every hedge fund
Raised more than 84% of the 1,060 hedge funds based in California, and more than 78% of all 10,308 that report sales.